CD276 and glioblastoma: In a database from Huashan Hospital of Fudan University, GBM patients with high B7-H3 expression (IRS > 6) had a median OS of 12 months, compared to 16 months in the low-expression group (IRS ≤ 6), with the difference being statistically significant (p = 0.042) [35].